S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

Fulgent Genetics Stock Price, Forecast & Analysis (NASDAQ:FLGT)

$12.41
+0.90 (+7.82 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$11.64
Now: $12.41
$12.48
50-Day Range
$9.09
MA: $11.30
$15.82
52-Week Range
$3.09
Now: $12.41
$16.50
Volume653,600 shs
Average Volume82,113 shs
Market Capitalization$232.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.93
Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLGT
CUSIPN/A
Phone626-350-0537

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.36 million
Book Value$2.83 per share

Profitability

Net Income$-5,610,000.00

Miscellaneous

Employees123
Market Cap$232.19 million
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable

Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.


Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics Inc (NASDAQ:FLGT) issued its quarterly earnings data on Monday, November, 4th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.08. The business had revenue of $10.35 million for the quarter, compared to analyst estimates of $8.48 million. Fulgent Genetics had a negative return on equity of 0.16% and a negative net margin of 3.52%. View Fulgent Genetics' Earnings History.

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Fulgent Genetics.

What price target have analysts set for FLGT?

2 brokerages have issued 12 month target prices for Fulgent Genetics' stock. Their forecasts range from $12.30 to $12.30. On average, they anticipate Fulgent Genetics' stock price to reach $12.30 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View Analyst Price Targets for Fulgent Genetics.

What is the consensus analysts' recommendation for Fulgent Genetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.

Has Fulgent Genetics been receiving favorable news coverage?

News articles about FLGT stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fulgent Genetics earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Fulgent Genetics.

Are investors shorting Fulgent Genetics?

Fulgent Genetics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 96,200 shares, a decrease of 29.1% from the September 30th total of 135,700 shares. Based on an average trading volume of 137,100 shares, the short-interest ratio is presently 0.7 days. Currently, 1.5% of the company's shares are sold short. View Fulgent Genetics' Current Options Chain.

Who are some of Fulgent Genetics' key competitors?

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), Zynerba Pharmaceuticals (ZYNE), Baidu (BIDU), Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA), Alibaba Group (BABA) and The Coca-Cola (KO).

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the folowing people:
  • Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
  • Mr. Paul Kim, Chief Financial Officer (Age 52)
  • Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Raymond James Trust N.A. (2.70%), Essex Investment Management Co. LLC (0.66%), Mutual Advisors LLC (0.57%) and Russell Investments Group Ltd. (0.01%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.

Which major investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Mutual Advisors LLC and Essex Investment Management Co. LLC. View Insider Buying and Selling for Fulgent Genetics.

Which major investors are buying Fulgent Genetics stock?

FLGT stock was acquired by a variety of institutional investors in the last quarter, including Raymond James Trust N.A. and Russell Investments Group Ltd.. View Insider Buying and Selling for Fulgent Genetics.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $12.41.

How big of a company is Fulgent Genetics?

Fulgent Genetics has a market capitalization of $232.19 million and generates $21.36 million in revenue each year. The company earns $-5,610,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.View Additional Information About Fulgent Genetics.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is http://www.fulgentgenetics.com/.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]


MarketBeat Community Rating for Fulgent Genetics (NASDAQ FLGT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  381
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Featured Article: What is the Quick Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel